• About us
• Contact

Advertisement

Collaboration › Details

JnJ–Chromatin Bioscience: synthetic promoter design, 202501– collab leveraging chromatinLENS platform

 

	Period	2025-01-20
	Partner, 1st	Johnson & Johnson Inc. (NYSE: JNJ) (JnJ)
	Partner, 2nd	Chromatin Bioscience Ltd.
	Product	chromatinLENS platform
	Product 2	advanced therapeutic product (gene therapy, cell therapy, tissue engineering products)

Chromatin Bioscience Ltd.. (1/20/25). "Press Release (News): Chromatin Bioscience Signs a Research Collaboration with Johnson & Johnson".

We are thrilled to be working with Johnson & Johnson, a leader in global healthcare innovation.

In this project, we will leverage our proprietary chromatinLENS platform to drive advancements in synthetic promoter design and its applications in transformative healthcare solutions.

This collaboration underscores the growing recognition of our platform's potential to deliver precise, cell-type-selective, and durable gene expression, supporting innovative approaches in gene and cell therapies.

We are excited to embark on this journey with Johnson & Johnson and look forward to the opportunities this collaboration will bring.

Record changed: 2025-04-20

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Chromatin Bioscience Ltd.. (2/20/25). "Press Release: Chromatin Bioscience Joins JLABS EMEA". Edinburgh....
• [2] Chromatin Bioscience Ltd.. (1/20/25). "Press Release (News): Chromatin Bioscience Signs a Research Collaboration with Johnson & Johnson"....
• [3] Basel Area Business & Innovation. (4/26/24). "Press Release: Johnson & Johnson Opens Innovation Hub in Allschwil"....
• [4] Recursion Pharmaceuticals, Inc.. (4/16/24). "Press Release: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer". Salt Lake City, UT....
• [5] Alia Therapeutics S.r.l.. (5/5/23). "Press Release: Alia Therapeutics Names Letizia Goretti as Chief Executive Officer". Milan....
• [6] F-Star Therapeutics Ltd.. (10/20/21). "Press Release: F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics". Cambridge & Cambridge, MA....
• [7] Mestag Therapeutics Ltd.. (5/18/21). "Press Release: Mestag Therapeutics Announces Collaboration with Janssen, Focused on the Discovery of Novel Fibroblast Targets for the Treatment of Inflammatory Disease". Cambridge....
• [8] Nouscom AG. (12/11/20). "Press Release: Nouscom Appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer". Basel....
• [9] Actimed Therapeutics Ltd.. (10/30/19). "Press Release: Actimed Therapeutics Appoints Robin Bhattacherjee as CEO". Ascot....
• [10] MeiraGTx Holdings plc. (8/7/19). "Press Release: MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.